Monitoring of chemotherapy response in malignant pleural mesothelioma using fluorodeoxyglucose positron emission tomography.
We report a 56-year-old man who underwent monitoring of the response to chemotherapy of malignant pleural mesothelioma (MPM). (8)F-fluoro-2-deoxy-(D)-glucose positron emission tomography (FDG-PET) and computed tomography (CT) were performed prior to chemotherapy and after the first and second courses of chemotherapy. The tumor lesion exhibited shrinkage on CT and a decrease in the standardized uptake value (SUV) max after the first course of chemotherapy, but exhibited size enlargement and an increase in SUV max after the second course of chemotherapy. These findings suggest that results of quantification of metabolic response by FDG-PET are related to the objective response as determined by CT in patients with MPM.
Kimura
Tatsuo
T
Department of Respiratory Medicine, Osaka City University, Osaka. kimutats@med.osaka-cu.ac.jp
Koyama
Koichi
K
Kudoh
Shinzoh
S
Kawabe
Joji
J
Yoshimura
Naruo
N
Mitsuoka
Shigeki
S
Shiomi
Susumu
S
Hirata
Kazuto
K
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D049268:Positron-Emission Tomography / Q000379:methods*
D000970:Antineoplastic Agents; D019788:Fluorodeoxyglucose F18